Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge assists Nuevolution in connection with Amgen’s cash offer
Mandate

Vinge assists Nuevolution in connection with Amgen’s cash offer

May 22, 2019 Capital Markets and Public M&A

Vinge has assisted Nuevolution AB (publ) (“Nuevolution”) in connection with the cash offer to the shareholders in Nuevolution by Amgen Inc. (“Amgen”).

Nuevolution is a molecule drug discovery biotech company, listed on Nasdaq Stockholm. 

Amgen is one of the world’s leading biotechnology companies, with a vision deeply rooted in innovative science. Amgen’s shares are listed on Nasdaq in the United States.

Amgen offers SEK 32.50 in cash for every share in Nuevolution. The offer value amounts to approximately SEK 1,610 million.
 
Vinge’s team has primarily consisted of David Andersson, Dain Hård Nevonen, Ludvig Frithiof and William Kåge.

Related

Vinge has advised Terranor Group AB in connection with its listing on Nasdaq First North Growth Market

 Vinge has advised Terranor Group AB (publ) (“Terranor”) connection with its listing on Nasdaq First North Growth Market. The first day of trading in Terranor's shares is today 30 June 2025.
June 30, 2025

Vinge advises Keyto Group in connection with the acquisition of GreenThumb

KEYTO Group expands into the UK market as GreenThumb joins the group. This partnership marks KEYTO’s first entry in the UK and reinforces its ambition to build the leading, tech-enabled one-stop destination for home-related services internationally.
June 30, 2025

Vinge advises Odevo in the acquisition of Portik Group

 Vinge has advised Odevo, the internationally leading company within residential property management, in connection with the acquisition of Portik Group. Through the acquisition, Odevo continues its international expansion by establishing itself in Spain, Italy, Portugal and Mexico.
June 27, 2025